Emfogen 25 MG


Emfogen 25 MG


Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)


Indications of Emfogen 25 Tablet

EmfogenTM is indicated

  • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
  • to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease


Pharmacology of Emfogen 25 Tablet

Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. The SGLT2 cotransporter is responsible for the reabsorption of glucose from the renal glomerular filtrate. The diabetic effect of SGLT2 inhibition reduces renal absorption and lowers the kidney’s glucose threshold, leading to increased glucose excretion. In addition, it also helps reduce high blood sugar levels, aids in weight loss, and lowers blood pressure.


Dosage & Administration of Emfogen 25 Tablet

The recommended dose of Empagliflozin is 10 mg once daily, taken in the morning, with or without food. In patients tolerating Empagliflozin, the dose may be increased to 25 mg once daily. In patients with volume depletion, correcting this condition prior to initiation of Empagliflozin is recommended.


Interaction of Emfogen 25 Tablet

Diuretics: Co-administration of Empagliflozin with diuretics resulted in increased urine volume.

Insulin or Insulin Secretagogues: Co-administration of Empagliflozin with insulin or insulin secretagogues increases the risk for hypoglycemia.

Positive Urine Glucose Test: Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Use alternative methods to monitor glycemic control.

Interference with 1,5-anhydroglucitol (1,5-AG) Assay: Monitoring glycemic control with 1,5-AG assay is not recommended as measurement of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors.

Use alternative methods to monitor glycemic control.



Empagliflozin is contraindicated in patients with history of serious hypersensitivity reaction to Empagliflozin or any of its ingredients, severe renal impairment, end-stage renal disease, or dialysis.


Side Effects of Emfogen 25 Tablet

The most common adverse reactions associated with Empagliflozin (5% or greater incidence) are urinary tract infections and female genital mycotic infections.


Pregnancy & Lactation

There are no adequate and well-controlled studies of Empagliflozin in pregnant women. Empagliflozin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if Empagliflozin is excreted in human milk. It is not recommended when breastfeeding.


Precautions & Warnings

Assessment of renal function is recommended prior to initiation of Empagliflozin and periodically thereafter. Empagliflozin should not initiated in patients with an eGFR less than 45 mL/min/1.73m2.No dose adjustment is needed in patients with an eGFR greater than or equal to 45 mL/min/1.73m2.


Therapeutic Class

Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors


Storage Conditions

Store in a cool (below 30°C) and dry place, away from light. Keep out of reach of children.


Pharmaceutical Name of Emfogen 25 Tablet

General Pharmaceuticals Ltd


Generic of Emfogen 25 Tablet